NUVL
HealthcareNuvalent, Inc. · Biotechnology · $8B
What is Nuvalent, Inc.?
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. Based in Cambridge, Massachusetts, the company is building a pipeline of precision oncology treatments designed to overcome drug resistance and reach tumors in the brain.
Nuvalent develops small-molecule inhibitors that target specific cancer-driving genetic alterations, particularly ROS1 and ALK fusions. Its approach emphasizes brain penetrance — meaning its drug candidates are engineered to cross the blood-brain barrier — and selectivity designed to remain effective even when tumors develop resistance to earlier-generation treatments. The company does not yet generate product revenue, as both lead programs are in active clinical trials.
Nuvalent was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
- NVL-520: brain-penetrant ROS1-selective inhibitor in Phase I development
- NVL-655: brain-penetrant ALK-selective inhibitor in Phase I/II clinical trial
- Resistance-overcoming mechanism design for next-generation oncology
- CNS-focused drug engineering targeting brain metastases
Is NUVL a Good Stock to Buy?
UQS Score rates NUVL as Poor overall, reflecting the realities of its early clinical-stage profile.
The one standout in Nuvalent's pillar profile is Risk, which scores Good — suggesting the company's balance sheet and near-term financial stability are relatively managed for a pre-revenue biotech. This is meaningful context for investors weighing the binary nature of clinical-stage bets.
Quality, Moat, Growth, and Valuation all register as Weak or Elevated, which is consistent with a company that has no approved products, no revenue, and a market price that already reflects significant pipeline optimism.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does NUVL pay dividends?
No — Nuvalent, Inc. does not currently pay a dividend.
Nuvalent does not pay a dividend, which is typical for clinical-stage biopharmaceutical companies. All available capital is directed toward funding clinical trials, research operations, and pipeline advancement. Income-focused investors should note that dividend initiation is unlikely until the company achieves regulatory approval and commercial revenue.
When does NUVL report earnings?
Nuvalent reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue company, Nuvalent's quarterly reports center on cash runway, operating expenses, and clinical trial progress rather than traditional revenue or profit metrics. Investors typically focus on pipeline milestones and updated trial data disclosures.
For the most recent quarter's results and clinical updates, visit Nuvalent's investor relations page directly.
NUVL Price History
+487.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Nuvalent, Inc.?
Based on Nuvalent, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
NUVL Long-term Outlook
Nuvalent's fundamental outlook is shaped almost entirely by clinical trial outcomes. With Growth and Quality both rated Weak, the company's near-term trajectory depends on whether NVL-520 and NVL-655 generate compelling efficacy and safety data. The Valuation pillar is rated Elevated, meaning the current market price appears to already embed a degree of pipeline success. A Risk rating of Good provides some reassurance that the company is not in immediate financial distress, but the path to value creation remains contingent on regulatory and clinical milestones.
Growth drivers
- Positive Phase I/II readouts for NVL-655 in ALK-positive cancers
- Clinical advancement of NVL-520 in ROS1-fusion cancers with CNS involvement
- Potential partnership or licensing activity driven by differentiated resistance mechanisms
Key risks
- Clinical trial failure or disappointing efficacy data for either lead program
- Elevated valuation leaving limited margin of safety if pipeline progress slows
- Ongoing cash consumption with no product revenue to offset operating costs
NUVL vs Peers
Nuvalent operates in a competitive clinical-stage oncology landscape alongside other development-focused biotechs.
Abivax focuses on chronic inflammatory diseases rather than oncology, pursuing a distinct therapeutic area with different regulatory and commercial dynamics.
ImmunityBio pursues immunotherapy and cell-based cancer treatments, representing a different mechanistic approach to oncology compared to Nuvalent's small-molecule inhibitor strategy.
Krystal Biotech develops gene therapy treatments for rare skin diseases, operating in a separate disease category with a more advanced commercial stage than Nuvalent.
Frequently Asked Questions
What does Nuvalent do?
Nuvalent is a clinical-stage biopharmaceutical company developing targeted cancer therapies. Its lead programs are small-molecule inhibitors designed to treat ROS1- and ALK-driven cancers, with a particular focus on brain penetrance and overcoming resistance to existing treatments.
Does NUVL pay dividends?
No, Nuvalent does not pay a dividend. The company is pre-revenue and directs its capital toward clinical development. Dividend payments are not typical for clinical-stage biotechs and are unlikely until the company reaches commercial-stage operations.
When does NUVL report earnings?
Nuvalent reports on a quarterly basis, as required for US-listed public companies. Because it has no product revenue, reports focus on cash position and trial updates. Check Nuvalent's investor relations page for the most current schedule.
Is NUVL a good stock to buy?
UQS Score rates NUVL as Poor overall, driven by Weak ratings across Quality, Moat, and Growth pillars, alongside an Elevated Valuation. The Risk pillar is rated Good, which is a relative positive. Whether NUVL fits a portfolio depends on an investor's tolerance for clinical-stage binary risk.
Is NUVL overvalued?
The UQS Valuation pillar for NUVL is rated Elevated, suggesting the current market price reflects meaningful pipeline optimism. For a pre-revenue company, valuation is largely driven by clinical expectations rather than current financial performance. Pro members can view the detailed valuation metrics.
How does NUVL compare to its competitors?
Nuvalent's closest listed peers — Abivax, ImmunityBio, and Krystal Biotech — each operate in distinct therapeutic areas or at different development stages. Nuvalent's differentiation lies in its brain-penetrant, resistance-overcoming mechanism design within precision oncology.
What is NUVL's market cap bracket?
NUVL is classified as a mid-cap stock. For a clinical-stage biotech with no approved products, this reflects substantial market expectations around pipeline potential rather than current revenue or earnings.
Who founded Nuvalent?
Nuvalent was incorporated in 2021. Founding and leadership details are publicly available through the company's official website and SEC filings, which provide the most accurate and current information.
Is NUVL a long-term quality indicator?
From a long-term quality perspective, NUVL's UQS profile is currently Poor, with most pillars rated Weak. Long-term quality typically requires demonstrated revenue, durable competitive advantages, and financial consistency — none of which a clinical-stage company has yet established. Pipeline success could change this picture materially.
What is the main competitive advantage of Nuvalent?
Nuvalent's scientific differentiation centers on brain-penetrant drug design and next-generation resistance mechanisms. Its inhibitors are engineered to remain active against mutations that limit earlier-generation treatments, which addresses a real unmet need in ROS1- and ALK-positive cancers.
What sector does NUVL belong to?
NUVL belongs to the Healthcare sector, specifically within clinical-stage biopharmaceuticals. Investors can explore other [Healthcare sector stocks scored by UQS](/sector/healthcare) to compare quality profiles across the industry.
Is NUVL a growth stock or value stock?
Based on UQS pillar labels, NUVL carries a Weak Growth rating and an Elevated Valuation — a combination that does not fit neatly into either category. It is best understood as a speculative clinical-stage biotech where value is contingent on future trial outcomes.
Unlock Full NUVL Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics behind each pillar rating
- ✓Compare NUVL against sector peers by quality score
- ✓Track pillar changes as new clinical data emerges
- ✓Screen for higher-quality biotech alternatives
Pro Analysis
NUVL — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | 13.4 | 0.0 | 11.0 | 0.0 | 71.2 | 0.0 | +3.7 |
| May 9, 2026 | 9.7 | 0.0 | 11.0 | 0.0 | 46.2 | 0.0 | -3.3 |
| Apr 2, 2026 | 13.0 | 0.0 | 11.0 | 0.0 | 68.0 | 0.0 | — |
NUVL — Pillar Breakdown
Quality
— 0.0/100 (25%)Nuvalent, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Nuvalent, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 71.2/100 (15%)Nuvalent, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Nuvalent, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)Nuvalent, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for NUVL.
Score Composition
Financial Data
More Stock Analysis
How is the NUVL UQS Score Calculated?
The UQS (Unified Quality Score) for Nuvalent, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Nuvalent, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Nuvalent, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.